Stylized representation of the NextPoint logo icon, featuring immunotherapy-related cellular imagery

expanding the potential
of immunotherapy

One pathway,
many possibilities

NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 checkpoint axis. Our innovative approach integrates foundational science with a defined clinical biomarker strategy to deliver a new class of monotherapies for patients who do not benefit from PD-1/L1 inhibitors. NextPoint is simultaneously advancing therapeutic approaches utilizing the unique upregulation of HHLA2 in cancer as an anchor for tumor-targeting therapeutic modalities. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology and beyond.

 

world-class team.

scientific
founders.

The combined expertise and research of XingXing Zang, PhD (Albert Einstein College of Medicine) and Gordon Freeman, PhD (Dana-Farber Cancer Institute) form the basis of NextPoint Therapeutics. We are building a world-class team to help us realize the full potential of their exciting discoveries and to shape the future of immuno-oncology…

Headshot of XingXing Zang, PhD, of Albert Einstein College of Medicine
XingXing Zang, PhD
Albert Einstein College of Medicine
Headshot of Gordon Freeman, PhD, of Dana-Farber Cancer Institute
Gordon Freeman, PhD
Dana-Farber Cancer Institute
leadership.
IvanCheung

Ivan Cheung, MBA

Chief Executive Officer

Paul-Conrad

Paul Conrad, PhD, MBA

Chief Business Officer

Leena-Gandhi

Leena Gandhi, MD, PhD

Chief Medical Officer

Tatiana-Novobrantseva

Tatiana Novobrantseva, PhD

Chief Scientific Officer

investors & partners.
Logo for MPM Capital, powering breakthroughs in life sciences

news.

February 20, 2024

NextPoint Therapeutics Announces First Patient Dosed in Phase 1a/b Clinical Trial of NPX887, a Novel Therapeutic Targeting HHLA2 to Reactivate Exhausted T and NK Cells in HHLA2+ Solid Tumors

February 14, 2024

NextPoint Therapeutics Announces Closing of Series B Financing Extension led by Catalio Capital Management

February 1, 2024

NextPoint Therapeutics Appoints Ivan Cheung as Chief Executive Officer 

January 16, 2024

NextPoint Therapeutics Appoints Tatiana Novobrantseva, PhD, as Chief Scientific Officer

December 7, 2023
NextPoint Therapeutics Announces IND Clearance from the FDA to Advance NPX887, a Novel Therapeutic Targeting HHLA2 to Reactivate Exhausted T and NK Cells in HHLA2+ Solid Tumors

November 10, 2023

NextPoint presented a new poster at the CRI-ENCI-AACR Seventh International Cancer Immunotherapy Conference in Milan, Italy

August 17, 2023

NextPoint Therapeutics Announces First Patient Dosed in Phase 1a/b Clinical Trial of NPX267, a Novel Therapeutic Targeting KIR3DL3 to Reactivate Exhausted T and NK Cells in HHLA2+ Solid Tumors

March 21, 2023

Axel Hoos, MD, PhD, Joins NextPoint Therapeutics Board of Directors

February 21, 2023
NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical Officer
January 10, 2023

NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs

What’s NEXT for you?

Research Associate

© nextpoint 2023. All Rights Reserved.

LabCentral, 238 Main Street, 5th Floor, Cambridge, MA 02142
info@nextpointtx.com    |    508-204-1115

Privacy Policy            Terms Of Use

NextPoint Therapeutics Announces First Patient Dosed in Phase 1a/b Clinical Trial of NPX887, a Novel Therapeutic Targeting HHLA2 to Reactivate Exhausted T and NK Cells in HHLA2+ Solid Tumors

Progressing clinical programs NPX267 and NPX887 in parallel to interrogate HHLA2/B7-H7 axis from multiple angles for optimizing targeted immuno-oncology therapeutic approaches

Cambridge, MA – February 20, 2024 – NextPoint Therapeutics, a clinical-stage biotechnology company developing a new class of precision oncology therapeutics targeting the novel HHLA2 pathway, announced today that the first patient has been dosed with NPX887 in a Phase 1 first-in-human clinical trial for the treatment of patients with solid tumors expressing HHLA2/B7-H7, a tumor antigen strongly upregulated in many human tumors independently of PD-L1.

The study is a Phase 1a/1b open-label, multi-center trial (NCT06240728) consisting of a dose escalation and an expansion stage to evaluate the tolerability, pharmacokinetics, immunogenicity and biomarker-based selection of NPX887 in patients with solid tumor malignancies including non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), colorectal carcinoma (CRC) and other solid tumor types known to express HHLA2/B7-H7. 

“The launch of NPX887, our second clinical program targeting the HHLA2/B7-H7 axis, marks an important step in broadening our therapeutic targeting of this novel pathway to reactivate the immune system to fight cancer,” commented Leena Gandhi, MD, PhD, Chief Medical Officer of NextPoint Therapeutics. “Together with NPX267, our first clinical program targeting the KIR3DL3 receptor for HHLA2, we are well-positioned to interrogate how best to exploit this pathway to effectively treat patients whose tumors express HHLA2 as an independent checkpoint of tumor-immune response from PD-L1. Our goal for both clinical programs is to leverage HHLA2 as a biomarker to enable precision selection of patients most likely to benefit. Both NPX267 and NPX887 have the potential for monotherapy benefit in selected patient populations.”

About NPX887

NPX887 is a fully human monoclonal antibody targeting HHLA2 (B7-H7), a novel immune checkpoint and tumor target antigen highly expressed in many cancers independently of PD-L1. NPX887 is designed to prevent immune escape in solid tumors by blocking KIR3DL3-mediated immunosuppression which results from binding to HHLA2. Treatment with NPX887 is believed to promote both T and NK cell antitumor activity within the tumor microenvironment. To learn more, visit www.clinicaltrials.gov (NCT06240728).

About NextPoint Therapeutics

NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 axis, also known as B7-H7. Our innovative approach integrates foundational science with a defined clinical biomarker strategy to deliver a new class of monotherapies for patients who do not benefit from PD-1/L1 inhibitors and other therapies. NextPoint is simultaneously advancing therapeutic approaches utilizing the unique upregulation of HHLA2 in cancer as an anchor for tumor-targeting therapeutic modalities. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology and beyond. To learn more, visit nextpointtx.com.

Contacts

Media Contact

Chelsea Rule
MacDougall Advisors
1(781)235-3060
crule@macdougall.bio

NextPoint Therapeutics Announces Closing of Series B Financing Extension led by Catalio Capital Management

Total of $122.5M Series B funding includes $42.5M Extension from new and existing investors

Financing propels company to transform the potential of immunotherapy into precision oncology by leveraging HHLA2/B7-H7 for both immunomodulation and direct tumor-targeting

Cambridge, MA – February 14, 2024 – NextPoint Therapeutics, a clinical-stage biotechnology company developing a new class of precision oncology therapeutics targeting the novel HHLA2 pathway, announced today the closing of a $42.5M Extension to its Series B financing round resulting in a total of $122.5M raised in the Series B financing. The funds will be used to advance the company’s two immuno-oncology clinical programs, NPX267 and NPX887, as well as propel the development of additional therapeutic modalities in the pipeline that target the novel HHLA2 tumor antigen.

The Extension was led by existing investor Catalio Capital Management, and as part of the financing, R. Jacob Vogelstein, PhD, has joined the NextPoint Board of Directors. Catalio is joined by other existing investors including MPM BioImpact, Leaps by Bayer, Sanofi Ventures, Invus, Sixty Degree Capital, Dana-Farber Cancer Institute’s Binney Street Capital and NextPoint founder Gordon Freeman, PhD. Along with Catalio, new investors Arkin Bio-Capital and WTT investment Ltd were the largest participants in this fundraising.

“Catalio is committed to investing in the next generation of category-defining life sciences companies and NextPoint’s mission of delivering groundbreaking new options to more patients with cancer strongly resonates with our own,” said R. Jacob Vogelstein, PhD, Co-Founder & Managing Partner of Catalio Capital Management. “We are delighted to support the company’s pipeline growth and advancement and look forward to being a strong partner for the future.”

“This financing strategically expands NextPoint’s group of high-quality investors and further transforms the company’s innovative pipeline to progress monotherapy treatments with a novel clinical biomarker,” commented Detlev Biniszkiewicz, PhD, Chairman of NextPoint’s Board of Directors. “We are excited to reshape immunotherapy into precision oncology and give hope to patients living with cancer.”

“This new round of financing underscores the support and confidence of our premier syndicate of investors, and we are well positioned to build upon our growing pipeline of multi-modal therapeutics targeting the novel HHLA2 pathway,” said Ivan Cheung, CEO of NextPoint. “We are advancing a diverse set of assets into clinical trials to exploit HHLA2’s role as both a novel immune checkpoint and a tumor-targeting mechanism. We are thrilled to pioneer a new class of monotherapies to treat both hot and cold tumors.”

About NextPoint Therapeutics

NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 axis, also known as B7-H7. Our innovative approach integrates foundational science with a defined clinical biomarker strategy to deliver a new class of monotherapies for patients who do not benefit from PD-1/L1 inhibitors. NextPoint is simultaneously advancing therapeutic approaches utilizing the unique upregulation of HHLA2 in cancer as an anchor for tumor-targeting therapeutic modalities. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology and beyond. To learn more, visit nextpointtx.com.

Contacts

Media Contact

Chelsea Rule
MacDougall Advisors
1(781)235-3060
crule@macdougall.bio

NextPoint Therapeutics Appoints Ivan Cheung as Chief Executive Officer

 Accomplished leader brings track record of value creation with scientifically unique assets to drive the company’s next phase of growth toward clinical success 

Cambridge, MA – February 1, 2024 – NextPoint Therapeutics, a clinical-stage biotechnology company developing a new class of precision oncology therapeutics targeting the novel HHLA2 pathway, today announced the appointment of Ivan Cheung as Chief Executive Officer (CEO) and to the Board of Directors. 

Mr. Cheung brings 25 years of drug development, approval and product launch achievements, and organizational leadership experience to NextPoint, most recently serving as Eisai’s U.S. CEO. With his appointment, NextPoint aims to deliver breakthrough clinical outcomes from precision immuno-oncology therapeutics targeting the HHLA2 checkpoint axis and create additional modalities leveraging HHLA2 as a novel tumor antigen. 

Mr. Cheung succeeds Detlev Biniszkiewicz, PhD, Managing Director at MPM BioImpact, who successfully led the company from its inception in 2018 and will continue to serve as the Chairman of the NextPoint Board of Directors. Under Dr. Biniszkiewicz’s leadership, NextPoint raised Series A and B funding and was transformed into a clinical-stage company. 

“We are thrilled to welcome Ivan to NextPoint and his proven leadership, deep industry expertise and commitment to scientific innovation make him the ideal person to shepherd the company into this exciting next chapter,” said Dr. Biniszkiewicz. “Ivan’s leadership was instrumental in bringing the targeted anti-cancer therapy lenvatinib and the first disease-modifying therapy for Alzheimer’s disease lecanemab to reach patients worldwide. I extend my heartfelt gratitude to the dedicated team at NextPoint who have made my time here so rewarding and am honored to chair the esteemed Board and continue contributing to the company’s success and growth.” 

Ivan Cheung, CEO of NextPoint, commented, “NextPoint exemplifies what is next in oncology innovation and I am pleased to join this stellar team to make a lasting impact in the lives of cancer patients and their families. My life-long passion is to create positive social impact and advance public health by means of breakthrough medications, and NextPoint is the ideal place to translate that goal into reality. I look forward to building upon the strong foundation that Detlev has created and work with our incredible team in this next phase of growth to establish NextPoint as a high-value biotechnology company.” 

At Eisai, Mr. Cheung guided the significant growth of the North America business to over $1.5 billion in revenue. Under his leadership, lenvatinib was successively launched in a range of tumor types, and combination clinical trials with a PD-1 inhibitor were initiated. In addition, Mr. Cheung led the groundbreaking development and the first-ever full U.S. approval for lecanemab, a monoclonal antibody therapeutic to treat the underlying pathophysiology of early-stage Alzheimer’s disease. His stewardship also led to the first wide reimbursement access from the Centers for Medicare & Medicaid Services for this class of medicines. Prior to Eisai, he was at Booz Allen Hamilton where he provided strategic and operational advice to pharmaceutical and biotech companies. Mr. Cheung received an MBA from Harvard Business School and a BSE from Duke University. 

About NextPoint Therapeutics 

NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 checkpoint axis. Our innovative approach integrates foundational science with a defined clinical biomarker strategy to deliver a new class of monotherapies for patients who do not benefit from PD-1/L1 inhibitors. NextPoint is simultaneously advancing therapeutic approaches utilizing the unique upregulation of HHLA2 in cancer as an anchor for tumor-targeting therapeutic modalities. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology and beyond. To learn more, visit nextpointtx.com. 

Contacts

Media Contact

Chelsea Rule
MacDougall Advisors
1(781)235-3060
crule@macdougall.bio

NextPoint Therapeutics Appoints Tatiana Novobrantseva, PhD, as Chief Scientific Officer

Cambridge, MA – January 16, 2024 – NextPoint Therapeutics, a clinical-stage biotechnology company developing precision immuno-oncology therapeutics targeting the novel HHLA2 pathway, today announced the appointment of Tatiana Novobrantseva, PhD, as Chief Scientific Officer (CSO).

Dr. Novobrantseva brings deep knowledge and broad experience in immunology/inflammation, cancer, immuno-oncology, autoimmunity and fibrosis to NextPoint, along with an outstanding record of accomplishment in drug development across immuno-oncology discovery and antibody development.

“Tatiana is a star in the immuno-oncology world, and we are thrilled to welcome her to the NextPoint team,” said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. “Her strategic leadership and entrepreneurial spirit will be instrumental during this pivotal time for NextPoint’s growth as we advance our precision immuno-oncology programs targeting the HHLA2 pathway.”

Dr. Novobrantseva co-founded Verseau Therapeutics in 2017 and served as Chief Scientific Officer for over 5 years, advancing immunotherapies stimulating macrophage repolarization to initiate anti-cancer immune responses, and is currently an Advisor to Verseau. Additionally, Dr. Novobrantseva previously led oncology discovery and development projects at Moderna as Chief Scientific Officer, Immuno-Oncology Research. She serves on the Scientific Advisory Boards of Voro Therapeutics and FairJourney Biologics, as well as on the Advisory Board for the mentorship organization Women in the Enterprise of Science and Technology.

After earning a PhD from the University of Cologne in Germany, Dr. Novobrantseva completed postdoctoral research at Harvard Medical School in the laboratory of Dr. Klaus Rajewsky on B cell immunology and autoimmunity. She advanced in industry as a scientist at Biogen and Alnylam Pharmaceuticals. Dr. Novobrantseva then participated in building Jounce Therapeutics as Director of Research, leading programs to reactivate the immune system against cancer, before consulting on a freelance basis on immunological aspects of drug development for various biopharma companies, developing scientific strategies across therapeutic areas for discovery and preclinical development.

“NextPoint takes a highly innovative approach to harnessing the immune system to fight cancer, which has been a personal mission of mine for more than a decade,” commented Dr. Novobrantseva. “I am thrilled to build on this exciting approach to deliver novel, precision immuno-oncology therapeutics to patients with currently intractable cancers.”

About NextPoint Therapeutics

NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Our innovative approach integrates foundational science with a defined clinical biomarker strategy to deliver a new class of monotherapies for patients who do not benefit from PD-1/L1 inhibitors. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. To learn more, visit nextpointtx.com.

Contacts

Media Contact

Chelsea Rule
MacDougall Advisors
1(781)235-3060
crule@macdougall.bio

NextPoint Therapeutics Announces IND Clearance from the FDA to Advance NPX887, a Novel Therapeutic Targeting HHLA2 to Reactivate Exhausted T and NK Cells in HHLA2+ Solid Tumors

NPX887, a monoclonal antibody targeting HHLA2, is designed to enhance immune responses in the tumor microenvironment

Cambridge, MA – December 7, 2023 – NextPoint Therapeutics, a clinical-stage biotechnology company developing precision immuno-oncology therapeutics targeting the novel HHLA2 pathway, today announced the acceptance of its investigational new drug (IND) application by the U.S. Food & Drug Administration (FDA) for NPX887. The company plans to initiate a first-in-human Phase I clinical trial in early 2024 evaluating NPX887 in patients with solid tumors known to express HHLA2, a tumor antigen strongly upregulated in many human cancers.

“NPX887 represents our second clinical program targeting the HHLA2 checkpoint axis. NextPoint’s approach is to advance therapeutics targeting this axis from different angles to prevent tumors from cloaking themselves from the immune system,” said Leena Gandhi, MD, PhD, Chief Medical Officer of NextPoint Therapeutics. “This important milestone allows us to advance our clinical evaluation of NPX887 and brings us one step closer to our goal of expanding treatment options for patients with cancer.”

About NPX887

NPX887 is a fully human monoclonal antibody targeting HHLA2 (B7-H7), a novel immune checkpoint and tumor target antigen highly expressed in many cancers independently of PD-L1. NPX887 is designed to prevent immune escape in solid tumors by blocking KIR3DL3-mediated immunosuppression upon binding to HHLA2. Treatment with NPX887 is believed to promote T and NK cell antitumor activity within the tumor microenvironment.

About NextPoint Therapeutics

NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Our innovative approach integrates foundational science with a defined clinical biomarker strategy to deliver a new class of monotherapies for patients who do not benefit from PD-1/L1 inhibitors. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. To learn more, visit nextpointtx.com.

Contacts

Media Contact

Chelsea Rule
MacDougall Advisors
1(781)235-3060
crule@macdougall.bio

NextPoint Therapeutics Announces First Patient Dosed in Phase 1a/b Clinical Trial of NPX267, a Novel Therapeutic Targeting KIR3DL3 to Reactivate Exhausted T and NK Cells in HHLA2+ Solid Tumors

First-in-class monoclonal antibody targeting KIR3DL3, the inhibitory receptor for HHLA2, designed to reverse immune suppression in the tumor microenvironment

The study will assess safety, tolerability and inform dosing strategy

Cambridge, MA – August 17, 2023 – NextPoint Therapeutics, a clinical-stage biotechnology company developing precision immuno-oncology therapeutics targeting the novel HHLA2 pathway, announced today that the first patient has been dosed with NPX267 in a Phase 1 first-in-human clinical trial for the treatment of patients with solid tumors known to express HHLA2, a tumor antigen strongly upregulated in many human tumors independently of PD-L1.

The Phase 1a/1b open-label, multi-center study (NCT05958199) consists of a dose escalation and an expansion stage to evaluate the tolerability, pharmacokinetics, immunogenicity and biomarker strategy of NPX267 in patients with metastatic solid tumors including epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) and other indications.

Killer cell immunoglobulin-like receptor 3DL3 (KIR3DL3) is expressed on effector T cells and natural killer (NK) cells in the tumor microenvironment and is an inhibitory receptor for the tumor antigen HHLA2, expressed on a range of solid tumors. Binding of KIR3DL3 to HHLA2 is believed to allow tumors to cloak themselves and hide from immune cells.

“Many cancers hijack the HHLA2 pathway to evade the immune system, whose signaling mechanisms were independently co-discovered by NextPoint’s scientific co-founders, Dr. XingXing Zang and Dr. Gordon Freeman,” said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. “Because HHLA2 is expressed independently of PD-L1 and is often highly expressed in PD-L1-negative cancers, targeting the HHLA2-KIR3DL3 interaction is a promising new approach for patients with cancer.”

“We are excited to launch the clinical evaluation of NPX267, our lead therapeutic program targeting the HHLA2 pathway,” said Leena Gandhi, MD, PhD, Chief Medical Officer of NextPoint Therapeutics. “This study will provide important data on the therapeutic activity of NPX267 as well as the mechanism of HHLA2-mediated immunosuppression via KIR3DL3 and inform our clinical strategy for developing precision immunotherapeutic treatments for patients.”

About NPX267

NPX267 is a first-in-class monoclonal antibody targeting KIR3DL3, the inhibitory receptor for the HHLA2 pathway (B7-H7), and is designed to prevent immune escape in solid tumors. By blocking the binding of KIR3DL3 on exhausted T and NK cells to HHLA2 expressed on tumor cells, NPX267 may be able to reactivate tumor antigen-primed immune cells in HHLA2-expressing solid tumors. Preventing KIR3DL3-mediated immune suppression may enhance anti-tumor immune responses for patients with HHLA2-positive cancers – a tumor antigen expressed independently of PD-L1. To learn more, visit www.clinicaltrials.gov (NCT05958199).

About NextPoint Therapeutics

NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. To learn more, visit nextpointtx.com.

Contacts

Media Contact

Chelsea Rule
MacDougall Advisors
1(781)235-3060
crule@macdougall.bio

Axel Hoos, MD, PhD, Joins NextPoint Therapeutics Board of Directors

Cambridge, MA – March 21, 2023 – NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that Axel Hoos, MD, PhD, has joined the NextPoint Board of Directors. Dr. Hoos currently serves as the Chief Executive Officer of Scorpion Therapeutics and brings a wealth of business, entrepreneurial and biopharmaceutical research and development expertise to the role.

“Dr. Hoos is a recognized pioneer in immuno-oncology and has shaped the checkpoint therapeutic landscape through his work on a new development paradigm for IO medicines and the development of the anti-CTLA-4 antibody ipilimumab, the first FDA-approved checkpoint immunotherapy,” commented Detlev Biniszkiewicz, PhD, CEO of NextPoint Therapeutics. “Our team will benefit greatly from Dr. Hoos’ expertise and perspective as we advance our novel immuno-oncology programs targeting the HHLA2 pathway to the clinic.”

“Immuno-oncology has become a critical component in our treatment armamentarium for cancer patients, and scientists are seeking the next breakthrough medicine to further expand its reach. I am looking forward to working with the executive team and fellow Board members to help NextPoint realize its promise to deliver the next IO breakthrough,” said Dr. Hoos. “NextPoint’s work on the HHLA2 pathway has the potential to expand the reach of precision immuno-oncology to a range of patients who do not benefit from currently available therapies.”

Prior to becoming CEO of Scorpion, Dr. Hoos served as Senior Vice President, R&D Governance Chair, and Therapeutic Area Head for Oncology at GlaxoSmithKline Pharmaceuticals (GSK). In that role, Dr. Hoos built the Oncology business across all therapeutic modalities in the focus areas of immuno-oncology, synthetic lethality, tumor cell targeting, epigenetics, and cell & gene therapy. He is a member of the Board of Trustees at the Sabin Vaccine Institute, Director on the Board of TCR2, and member of the Scientific Advisory Board and Co-Director of the Cancer Immunotherapy Consortium at the Cancer Research Institute. Dr. Hoos received his MD in Medicine from Heidelberg University, and his PhD in Molecular Oncology from the German Cancer Research Center. He trained in general surgery at the Technical University of Munich and as a fellow in cancer research at Memorial Sloan-Kettering Cancer Center.

About NextPoint Therapeutics

NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. To learn more, visit nextpointtx.com.

Media Contact

Chelsea Rule
MacDougall Advisors
crule@macdougall.bio

NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical Officer

Cambridge, MA – February 21, 2023 – NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).

As CMO, Dr. Gandhi will oversee the clinical development of NextPoint’s precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Dr. Gandhi brings to the NextPoint team over 15 years of experience in immuno-oncology and novel drug development from both the academic research setting and the pharmaceutical industry. She has led pivotal studies demonstrating the utility of PD-L1 as a biomarker for efficacy of anti-PD1 agents in lung cancer as well as studies demonstrating the value of combining immunotherapy and chemotherapy in the treatment of non-small cell lung cancer.

“Leena is a proven leader in immuno-oncology and a brilliant physician-scientist, and our team will benefit greatly from her academic and drug development expertise as NextPoint moves forward in its next stage of growth,” said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. “We thank Dr. Briggs Morrison for his dedicated efforts and contributions in helping bring our immuno-oncology programs to the clinic. Briggs Morrison, MD, will step down as Interim CMO, but will continue to advise the company on an ongoing basis.”

“I look forward to working with the NextPoint team to accelerate the development of programs targeting the HHLA2 pathway, a novel tumor-suppressive mechanism with the potential to impact many patients,” commented Dr. Gandhi. “NextPoint’s outstanding team of scientists who have characterized the HHLA2 pathway along with experienced drug developers in the management team makes for the ideal chemistry to usher these novel immuno-oncology programs into the clinic.”

Dr. Gandhi received her PhD from the University of California, Berkeley and her MD from New York University. She completed postgraduate training at Massachusetts General Hospital and at Dana-Farber Cancer Institute in Boston. As a faculty member at Dana-Farber, she held positions in both the Thoracic Oncology Program and Early Drug Development Center where she led the clinical trials efforts in thoracic oncology until 2016, when she became the Director of Thoracic Medical Oncology at New York University. In Dr. Gandhi’s next role as Vice President of Immuno-Oncology Development at Eli Lilly, she led the development of novel immuno-oncology agents across cancer types before returning to Dana-Farber in 2020, where she most recently served as the Director of the Center for Cancer Therapeutic Innovation a cross-malignancy novel therapeutics hub.

About NextPoint Therapeutics

NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. To learn more, visit nextpointtx.com.

Contacts

Media Contact

Lauren Arnold
MacDougall Advisors
1(617)694-5387
larnold@macdougall.bio

NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs

Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells

Cambridge, MA / Leverkusen, Germany – January 10, 2023 – NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. The financing will be used to advance NextPoint’s two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses.

Additional new investors in the round include Invus, Catalio Capital Management, Sixty Degree Capital and PagodaTree Partners. Existing investors that took part in the financing include MPM Capital Management, Dana-Farber Cancer Institute’s Binney Street Capital and NextPoint founder Gordon Freeman, PhD. As part of the financing, Rakhshita Dhar, Senior Director of Venture Investments Health at Leaps by Bayer, and Paulina Hill, Partner at Sanofi Ventures, will join the NextPoint Board of Directors.

NextPoint’s programs aim to deliver monotherapies for cancer patients without viable treatment options. While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. Similar to PD-L1, the tumor antigen HHLA2 is a member of the B7 receptor family1, is highly expressed on certain hard-to-treat cancers2, and drives avoidance of detection from the immune system. Importantly, HHLA2 is independent of PD-L1 and is often most strongly expressed in PD-L1-negative cancers. NextPoint’s approach re-activates immune cells in tumors that are suppressed by HHLA2-driven immune evasion.

NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. Drs. Freeman’s and Zang’s independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients3,4.

“NextPoint is building a deep understanding of the HHLA2 tumor-specific immune-escape mechanism, with the ultimate goal of establishing standalone treatments in cancers with high HHLA2 expression,” said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. “The support of our new investors along with the continued commitment of our existing investors and founders emphasizes our momentum and progress in defining precision immuno-oncology for new patient segments.”

Juergen Eckhardt, MD, Head of Leaps by Bayer, commented, “Leaps by Bayer was founded to help solve ten of the world’s biggest challenges in health and agriculture, including preventing and curing cancer. We are thrilled to support NextPoint, an exciting addition to our oncology portfolio, as it works to redefine the treatment landscape of immuno-oncology.”

About NextPoint Therapeutics

NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. To learn more, visit nextpointtx.com.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. R&D expenses before special items amounted to 5.3 billion euros. For more information, go to www.bayer.com.

About Leaps by Bayer

Leaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of today’s biggest challenges in health and agriculture. The investment portfolio includes more than 50 companies. They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. For more information, go to leaps.bayer.com.

About Sanofi Ventures

Sanofi Ventures is the corporate venture capital arm of Sanofi. Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofi’s business footprint, and digital health solutions. Find out more: www.sanofiventures.com

Contacts

Media Contact

Lauren Arnold
MacDougall Advisors
1(617)694-5387
larnold@macdougall.bio

Kira Peikoff
Leaps by Bayer
1(973)791-3348
kira.peikoff@bayer.com

  1. Zhao R, Chinai JM, Buhl S, et al. HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T cell function. Proc Natl Acad Sci U S A. 2013 Jun 11;110(24):9879-84.
  2. Janakiram M, Chinai JM, Fineberg S, et al. Expression, clinical significance, and receptor identification of the newest B7 family member HHLA2 protein. Clin Cancer Res. 2015 May 15;21(10):2359-66.
  3. Wei Y, Ren X, Galbo PM Jr, et al. KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. Sci Immunol. 2021 Jul 9;6(61):9792.
  4. Bhatt RS, Berjis A, Konge JC, et al. KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. Cancer Immunol Res. 2021 Feb;9(2):156-169.

Research Associate

Summary

NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. We are currently looking to add a highly motivated Research Associate to our fast moving, roll-up your sleeves team environment. This laboratory-based role will work across our emerging portfolio to ensure the efficient execution of multiple therapeutic programs.

 

Responsibilities

  • Design and perform ligand binding assays in multi-well formats to analyze novel antibody therapeutics
  • Develop and execute functional assays involving primary human immune cells, mammalian cell culture, and multi-color flow cytometry to screen novel antibody therapeutics in an immune-oncology setting
  • Work independently to design and conduct experiments, analyze, interpret, and communicate data in team meetings and to leadership
  • Support the laboratory organization and operations by maintaining lab equipment and managing reagent and supply inventories

 

Experience and Qualifications

  • Bachelor’s degree in cell/molecular biology, immunology, or cancer biology or equivalent field
  • 2 + years hands-on experience in drug discovery research preferably in an industry setting
  • Experience with cell-based functional immune assays such as MLR, immune cell activity assays, and cytokine release assays
  • Experience with multiparameter flow cytometry
  • Hands on experience with murine tumor models preferred
  • Excellent verbal and written communication skills with a demonstrated ability to work collaboratively and thrive in a team environment
  • Excellent interpersonal skills and willingness to learn a variety of new techniques and technologies; flexibility to adapt to rapidly changing priorities and deadlines

 

Medical Requirements

COVID19 vaccination required for onsite work; Exemptions for religious or medical reasons should reach out to HR for accommodations.

Interested in finding out more?
Please send your resume and cover letter to HR@nextpointtx.com.

Clinical Trial Manager / Senior Clinical Trial Manager

Summary

NextPoint Therapeutics, Inc. is an exciting development-stage Boston-area startup company working at the frontier of immuno-oncology on a novel checkpoint axis with multiple programs entering the clinic. We are currently looking to add a Clinical Trial Manager/Senior Clinical Trial Manager to our fast moving, roll-up your sleeves team environment. Reporting to the VP, Clinical Development Operations, the successful candidate will be responsible for all aspects of clinical trial management for two global phase 1 oncology studies.

What are we offering to you?

This is an outstanding opportunity to join a well-funded startup company early in its trajectory. You will be a vital part of a team striving transform cancer treatment and deliver patient cures. You will have a direct and significant impact on how we operationalize our clinical studies. You will also help to shape the NextPoint culture and be a part of a passionate, transparent, and collaborative work environment.

We are looking for someone who can bring significant capability to deliver on the operational needs of the role, while bringing a thoughtful perspective, drive for results, collaborative approach, and the ability to work with, influence, and communicate with a variety of stakeholders.

Responsibilities

  • You will oversee the day-to-day operations of study execution, with a focus on site oversight from study startup to study closeout, patient enrollment, monitoring, compliance, and data flow and metrics from the clinical sites, CROs and vendors.
  • You will work with both internal teams and external vendors to oversee logistics in relation to the collection and shipment of biological samples which will be obtained for the purpose of executing the translational objectives of our clinical trials.
  • You will collaborate with a dynamic NextPoint cross-functional team to deliver clinical studies that are on time and within budget guidelines, while ensuring quality in accordance with the protocol and ICH GCP guidelines.
  • You will develop and maintain strong relationships with investigators, clinical site staff, and CROs/vendors globally.
  • You will manage reports for communicating study progress and key metrics to Senior Management and program teams.
  • You will contribute to or author key study documents including, but not limited to, protocols, informed consent forms, case report forms, study plans, laboratory and pharmacy manuals and clinical study reports.
  • You will be accountable for effective vendor management by:
    • serving as primary point of contact for contracted CROs and other vendors
    • identifying potential risks and proactively resolving issues with CROs/vendors
    • ensuring CROs/vendor contracts meet requirements and are efficiently executed with key performance indicators
    • partnering with vendor to ensure accurate budgeting and accrual of costs throughout duration of each clinical study
  • You will ensure reliable quality data are delivered by reviewing monitoring reports, protocol deviations, clinical data listings and performing or overseeing site monitoring visits, as needed.
  • You will coordinate with CROs on site selection, IRB/EC submissions, site initiation and close-out planning.
  • You will provide oversight and ensure maintenance of clinical trial master files (TMF) to ensure compliance with required regulatory and ICH GCP quality standards..
  • You will participate in preparation of regulatory filings (e.g. IND, NDA, etc.), as needed.
  • You will ensure inspection readiness by collaborating with CROs and providing support to clinical sites to prepare for and respond to audit/inspection findings conducted by internal QA and external regulatory agencies.
  • You will assist with the onboarding and mentoring of new or junior clinical operations associates, as necessary.

 

Your Background:

  • BS/BA/RN Degree in science or a health related field is preferred
  • You should ideally have 5+ years of experience in clinical study management. Sponsor experience is strongly preferred.
  • You have experience in executing clinical studies across various phases is desirable. Expertise in oncology drug development is preferred.
  • You have a strong and current knowledge in global regulatory and compliance requirements including but not limited to US CFR, EU CTD, and ICH GCP applicable to the conduct of clinical trials
  • You have experience in CRO, vendor and laboratory oversight.
  • You are a motivated self-starter who is capable of flourishing in a fast-paced small company environment.
  • You have strong interpersonal and organizational skills, with a high degree of attention to detail.
  • Must be able to travel up to 10-20%, domestically and internationally
  • You are pragmatic and able to manage multiple projects and needs effectively.

 

Interested in finding out more?
Please send your resume and cover letter to HR@nextpointtx.com.

Director/Senior Director, Clinical Pharmacology

Summary

NextPoint Therapeutics is an exciting development-stage Boston-area startup company working at the frontier of immuno-oncology on a novel checkpoint axis with multiple programs entering the clinic. We are currently looking for a Director/Senior Director, Clinical Pharmacology to our fast moving, roll-up your sleeves team environment. Reporting to the Chief Medical Officer, the Director/Senior Director, Clinical Pharmacology will be responsible for all aspects of the clinical pharmacology strategy including early clinical development (phase I/II studies). We are a nimble, innovative, and driven company and looking for an experienced individual to join our growing team.

 

Responsibilities

  • Lead all aspects of the clinical pharmacology strategy including early clinical development (phase I/II studies)
  • Provide strategic leadership in development and execution clinical development plans that include development of dosing strategy, characterization and prediction of the pharmacokinetics, pharmacodynamics, and drug metabolism of the drug candidate in selected preclinical and all clinical areas
  • Manage all clinical study planning, review, data analysis / interpretation, and reporting of individual studies implemented to support clinical pharmacology components of project plans
  • Provide strategic quantitative clinical pharmacology input to cross functional clinical development teams
  • Determine scope, design, and planning and analysis of early and mid-stage pharmacokinetic (PK) and pharmacodynamic (PD) studies, and modeling/simulations required from a drug development and regulatory perspective to take a project from concept to NDA submission
  • Lead and prepare appropriate documents or sections of clinical protocols, clinical study reports with respect to Clinical Pharmacology studies or data
  • Author regulatory documents (IND’s, NDA’s, IB’s, etc.) and respond to regulatory inquires related to DMPK, PK/PD, and clinical pharmacology
  • Monitor work with CROs and other external vendors to ensure compliance with agreed protocols, quality standards and timelines (both with regard to bioanalysis and PK activities at CROs as well as with vendors in the setting of pK/pD modeling)
  • Review external data, lead analysis, interpretation and reporting of clinical pharmacokinetic and pharmacodynamic data

 

Experience and Qualifications

  • PhD, PharmD or equivalent training in Clinical Pharmacology, Pharmacokinetics, or a related field with 7+ years of biotech or pharmaceutical industry experience as a clinical pharmacologist with proven understanding of drug development
  • Strong knowledge of pharmacokinetics and pharmacodynamics principles, immunogenicity, modelling and simulation, Model-Informed Drug Development, ADME Concepts, and regulatory clinical pharmacology requirements to support clinical development and regulatory submission
  • Experienced in performing Modeling and Simulation (M&S) in drug development (ie Proficiency and experience in using common PK / PD modeling software packages (i.e., Phoenix WinNonlin, NONMEM, R, SAS, and other similar tools)
  • Excellent verbal and written communication and organizational skills required with demonstrated success in leading projects and interacting with cross functional teams
  • Ability to navigate, problem-solve, execute, and lead in a dynamic, fast-paced and evolving environment


To apply, please reach out to: Randy Rongione, rrongione@kleinhersh.com.

NextPoint Therapeutics Terms of Use

NextPoint Therapeutics, Inc. (“NextPoint,” “we,” “us” or “our”) has created a website at https://www.nextpointtx.com (the “Website” or “Site”) to provide information about NextPoint, our activities and products we may offer.

To assist you in using the Website, we have created (i) these Terms of Use (the “Terms”), and (ii) a Privacy Notice. Our Privacy Notice explains how we treat information that you provide to us through the Website and our Terms govern your use of our Website and Content. Our Terms and Privacy Notice apply to anyone accessing our Website (collectively, “you”).

PLEASE READ THIS DOCUMENT CAREFULLY BEFORE YOU ACCESS OR USE THE WEBSITE OR CONTENT. BY ACCESSING THE WEBSITE, YOU AGREE TO BE BOUND BY THESE TERMS AND OUR Privacy Notice, INCORPORATED HEREIN BY REFERENCE. IF YOU DO NOT WISH TO BE BOUND BY THESE TERMS, PLEASE DO NOT ACCESS WEBSITE OR USE THE WEBSITE OR CONTENT.

  1. Your Agreement. These Terms govern: (i) your use of the Website; (ii) your use of information obtained through the Website, including information, software, artwork, text, video, audio, pictures, content, trademarks, trade dress and other intellectual property owned by NextPoint or our licensors and made available to you through the Website (collectively, “NextPoint Content”). Please read these Terms carefully; they impose legal obligations on you and on NextPoint, and establish our legal relationship. By accessing our Website, you are acknowledging that you have read and understood these Terms and agree to be legally bound by them.
  2. Overview. The Website provides a venue to obtain information about NextPoint, our products, and product support.
  3. Ownership; Reservation of Rights. The Website and associated NextPoint Content are the proprietary property of NextPoint and our licensors, and are protected by U.S. and international copyright, trademark and other intellectual property laws, or are used under the principles of fair use. NextPoint and our licensors retain all rights with respect to the Website and NextPoint Content except those expressly granted to you in these Terms.
  4. Grant of Rights. Subject to your compliance with these Terms, you are granted the right to access our Website and NextPoint Content solely for your personal, non-commercial use. You shall not (i) license, sublicense, sell, resell, distribute or otherwise commercially exploit the Website or NextPoint Content to any third party; (ii) modify or make derivative works based upon the Website or NextPoint Content; or (iii) reverse engineer, reverse compile, or access the Website or NextPoint Content in order to build a competitive product or service.
  5. Comments/Feedback. Our Website may allow you to provide comments or feedback regarding our Website and our NextPoint Content. By providing comments/feedback, you grant us the right to use your comments and feedback for the purposes of improving the Website.
  6. Code of Conduct. As a condition to your use of the Website, you agree to follow our Code of Conduct, set out below. Under this Code, you will not:
    • Upload, email or otherwise transmit any images or other content that is unlawful, obscene, harmful, hateful, invades the privacy of any third party, contains nudity or pornography or is otherwise objectionable.
    • Disseminate materials that impact or invade the privacy of others, such as photographs, video clips, sound recordings, personally identifiable information, or other materials that reveal personal, private or sensitive information about another person, without that person’s consent.
    • Submit material that is intentionally false, defamatory, unlawfully threatening or unlawfully harassing.
    • Infringe any third party’s copyright, patent, trademark, trade secret or other proprietary rights or rights of publicity or privacy. Electronic materials – such as music, videos, games, images and text in electronic form – can easily be copied, modified and sent over networks (such as the internet). These electronic materials are thus extremely vulnerable to unauthorized distribution and copyright infringement. These materials may not be transmitted over the Website without the copyright owner’s permission or without a legitimate “fair use” justification for the transmittal.
    • Transmit materials that contain any viruses, Trojan horses, worms, time bombs, cancelbots or other computer-programming routines that are intended to damage, detrimentally interfere with, surreptitiously intercept or expropriate any system, data or personal information.
    • Use the Website to artificially generate traffic or page links to a website or for any other purpose not expressly allowed under these Terms.
    • Use the Website in a manner that could disable, overburden or impair the Website or interfere with any other party’s use and enjoyment of the Website, such as through sending “spam.”
    • Use the Website to test or reverse engineer the Website in order to find limitations, vulnerabilities or to evade filtering capabilities.
    • Seek to obtain access to any materials or information through “hacking”, “data harvesting” or through other means we have not intentionally made available to you through the Website.
    • Use the Website for any purpose that is unlawful or prohibited by these Terms. For example, you will not use the Website to violate any law, statute or regulation (including, without limitation, those governing export control, consumer protection, unfair competition, anti-discrimination or false advertising).
  7. Jurisdiction. Certain sections of our Website contain information about our products that are not available in all countries. Approved indications, dosages, restrictions and product presentations may vary from country to country where such products are sold. Information that we publish on the Internet may contain references or cross-references to our products, programs, and services that are not announced or available in your country. Such references do not imply that we intend to announce such products, programs, or services in your country. We reserve the right to limit provision of our products and services to any person, geographic region or jurisdiction and/or to limit the quantities of any products or services we provide. You may consult us at info@nextpointtx.com for information regarding the products, programs and services that may be available to you. Any offer for any product or service made in the materials on this Site is void where prohibited.
  8. Monitoring; Revocation or Suspension of Use Privileges. We reserve the right at any time to (i) monitor your use of the Website, and (ii) terminate or suspend your use of some or all of the Website if you engage in activities that we conclude, in our discretion, breach our Code of Conduct or otherwise violate these Terms or our Privacy Notice. Although we have no – and assume no – obligation to monitor activities on the Website, please understand that we may employ filters designed to detect and block inappropriate content described in our Code of Conduct. We reserve the right to request edits to your submission, to refuse to post or to remove any information or materials, in whole or in part, that we believe, in our sole discretion, is incompatible with our Code of Conduct.You should also understand that our Code of Conduct is based in many instances on principles of applicable law. Violations of our Code of Conduct accordingly may expose you to criminal charges, and civil liability to harmed parties for compensatory damages and attorney’s fees. NextPoint reserves the right at all times to disclose information it deems necessary to satisfy any applicable law, regulation, legal process or governmental request, consistent with our Privacy Notice.
  9. Links to Third-Party Sites. The Website may contain links or produce search results that reference links to third party websites (collectively, “Linked Sites”). NextPoint has no control over these Linked Sites or their content and does not assume responsibility or liability for any content, opinions or materials available on Linked Sites. NextPoint does not endorse the content of any Linked Site, nor does NextPoint warrant that a Linked Site will be free of computer viruses or other harmful code that can impact your computer or other web-access device. By using the Website to search for or link to another site, you agree and understand that such use is at your own risk.
  10. Warranty Disclaimer. NEXTPOINT DOES NOT PROMISE THAT THE WEBSITE WILL BE ERROR-FREE OR UNINTERRUPTED, OR THAT YOU WILL OBTAIN SPECIFIC RESULTS FROM YOUR USE OF THE WEBSITE OR YOUR USE OF ANY CONTENT, SEARCH OR LINK ON IT. THE WEBSITE AND NEXTPOINT CONTENT ARE DELIVERED ON AN “AS IS” AND “AS AVAILABLE” BASIS. WHEN YOU ACCESS THE WEBSITE, YOU DO SO AT YOUR OWN RISK. NEXTPOINT DOES NOT REPRESENT OR WARRANT THAT MATERIALS YOU DOWNLOAD FROM THE WEBSITE WILL BE FREE OF VIRUSES OR OTHER HARMFUL FEATURES.
    NEXTPOINT EXPRESSLY DISCLAIMS: (i) ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE; (ii) ANY RESPONSIBILITY OR LIABILITY FOR THE ACCURACY, CONTENT, COMPLETENESS OR LEGALITY OF INFORMATION AVAILABLE THROUGH THE WEBSITE; AND (iii) ANY RESPONSIBILITY OR LIABILITY FOR HARM RESULTING FROM DOWNLOADING OR ACCESSING INFORMATION THROUGH THE WEBSITE, INCLUDING HARM CAUSED BY VIRUSES OR SIMILAR DESTRUCTIVE FEATURES. YOU EXPRESSLY AGREE THAT USE OF THE WEBSITE AND RELATED CONTENT IS AT YOUR SOLE RISK.
  11. NO MEDICAL ADVICE. THE CONTENT ON THE WEBSITE IS PROVIDED FOR GENERAL INFORMATIONAL PURPOSES ONLY AND IS NOT INTENDED AS, NOR SHOULD IT BE CONSIDERED A SUBSTITUTE FOR, PROFESSIONAL MEDICAL ADVICE. YOU ACKNOWLEDGE THAT YOUR USE OF THE WEBSITE AND CONTENT CONTAINED THEREON IS VOLUNTARY. NEXTPOINT MAKES NO REPRESENTATIONS OR WARRANTIES WITH REGARD TO INFORMATION CONTAINED ON THE WEBSITE AND NEXTPOINT SHALL HAVE NO LIABILITY WITH REGARD TO SAME. IF YOU HAVE OR SUSPECT YOU HAVE A MEDICAL PROBLEM, PROMPTLY CONTACT YOUR PROFESSIONAL HEALTHCARE PROVIDER.
  12. Limitation of Liability. UNDER NO CIRCUMSTANCES, INCLUDING BUT NOT LIMITED TO, BREACH OF CONTRACT, TORT OR NEGLIGENCE, WILL NEXTPOINT BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, INCIDENTAL, PUNITIVE, EXEMPLARY OR CONSEQUENTIAL DAMAGES (INCLUDING LOST PROFITS) THAT ARISE OUT OF OR ARE RELATED TO YOUR USE OF THE WEBSITE OR NEXTPOINT CONTENT.
  13. Indemnity. You agree to defend, indemnify and hold harmless NextPoint and its subsidiaries, affiliates, licensors and service providers and its and their respective officers, directors, employees, contractors, agents, licesnors, suppliers, successors and assigns from and against any liability to third parties, including reasonable attorneys’ fees, arising from or related to your breach of these Terms.
  14. Modifications to these Terms. We may modify and change these Terms over time. We will not “retroactively” change these Terms, and any modifications we make shall take effect proactively, once you next access the Website. Please feel free to print out a copy of the current Terms for your records.
  15. Accessing the Website. We reserve the right to withdraw or amend this Website, and any service or material we provide on the Website, in our sole discretion without notice. We will not be liable if for any reason all or any part of the Website is unavailable at any time or for any period.
  16. Changes to Website. We may update the content on this Website from time to time, but its content is not necessarily complete or up-to-date. Any of the material on the Website may be out of date at any given time, and we are under no obligation to update such material
  17. Copyright Infringement. Certain materials available on the Website are our Works (content we own, authored, created, purchased, or licensed or which we shall own, author, create, purchase, or license). Our Works may be protected by copyright, trademark, patent, trade secret and/or other laws, and we reserve and retain all rights in our Works. We hereby grant you a limited non-assignable license to access and make personal use of the Website provided that such use is for the purposes of the Website described above. This license does not permit you to sell, license, and/or make any commercial use of our Website or its contents and materials and/ or any information derived from our Website or its contents and materials. No further publication or commercial use may be made of the materials on this Website without the express written permission of NextPoint. You may not make any part of this Website available as part of another web site whether by hyperlink framing on the internet or otherwise. This Website and its content may not be used to construct a database of any kind nor may the same be stored (in whole or part) in databases for access by you or any third party or to distribute any database containing all or part of the Website or its content.
    The above described license is conditioned on your compliance with these Terms, and shall terminate upon termination of these Terms. If you breach any provision of these Terms, any license you have obtained will be automatically rescinded and terminated.
  18. Assignment. These Terms shall not be assignable by you, either in whole or in part. NextPoint reserves the right to assign its rights and obligations under these Terms.
  19. General. These Terms shall be governed in all respects by the laws of the State of New York without giving effect to its conflicts of law provisions. Both parties submit to the personal jurisdiction of and venue in the state and federal courts in the State of New York, in the judicial district where NextPoint resides. The parties further agree that any cause of action arising under this Agreement shall exclusively be brought in such courts. If any provision of these Terms is held to be invalid or unenforceable, such provision shall be struck and the remaining provisions shall be enforced. Headings are for reference purposes only and in no way define, limit, construe, or describe the scope or extent of such section. NextPoint’s failure to act with respect to a breach by you or others does not waive its right to act with respect to subsequent or similar breaches. This agreement and the terms and conditions contained herein set forth the entire understanding and agreement between NextPoint and you with respect to the subject matter hereof and supersede any prior or contemporaneous understanding, whether written or oral.
  20. Waiver and Severability. No waiver of by us of any term or condition set forth in these Terms shall be deemed a further or continuing waiver of such term or condition or a waiver of any other term or condition, and any failure of us to assert a right or provision under these Terms shall not constitute a waiver of such right or provision. If any provision of these Terms is held by a court or other tribunal of competent jurisdiction to be invalid, illegal or unenforceable for any reason, such provision shall be eliminated or limited to the minimum extent such that the remaining provisions of the Terms will continue in full force and effect.
  21. Survival. The following provisions shall survive the termination of these Terms and shall apply indefinitely: (i) Section 3 (Ownership; Reservation of Rights); (ii) Section 10 (Warranty Disclaimer); (iii) Section 11 (Limitation of Liability); (iv) Section 13 (Indemnity); (v) Section 16 (Assignment); (vi) Section 19 (General); and (vii) Section 21 (Survival).
  22. Relationship to Privacy Notice. These Terms must be read in conjunction with our Privacy Notice. The provisions of our Privacy Notice are incorporated herein. To the extent these Terms conflict with the terms of our Privacy Notice, the terms of our Privacy Notice shall control.
  23. Contact Us. If you have any questions about these Terms, the practices of this Website, or your dealings with NextPoint, please contact us at:

info@nextpointtx.com

450 Kendall Street

Cambridge, MA 02142

24. Effective Date. The effective date of these Terms is May 18, 2022.

25. Copyright and Legal Notice. Copyright ©2022 NextPoint Therapeutics, Inc. All Rights Reserved.

NextPoint Therapeutics, Inc. Privacy Notice

LAST UPDATED: May 18, 2022

This Privacy Notice is intended to describe how NextPoint Therapeutics, Inc., (“NextPoint”) collects, uses, and shares Personal Data that you submit to us and that we collect through our website https://www.nextpointtx.com (the “Site”). The Site provides a venue to obtain information about NextPoint, our activities, and products we may offer.

INFORMATION WE COLLECT

For purposes of this Privacy Notice, “Personal Data” means any information relating to an identified or identifiable natural person. As described in detail below, we may collect certain Personal Data from or about you in connection with your use of, or your submissions to, the Site.

We may collect Personal Data as follows:

  • When we leverage and/or collect cookies, device IDs, location, data from the environment, and other tracking technologies. We may collect certain Personal Data using cookies and other technologies, such as web beacons, device IDs, geolocation, HTML5 local storage, Flash cookies, and IP addresses. We specifically use browser cookies for different purposes, including cookies that are strictly necessary for functionality and cookies that are used for personalization and performance/analytics. When you visit the Site, we may also automatically collect certain data about your device, including information about your device’s operating system, your web browser, IP address, and time zone. Additionally, as you browse the Site, we collect information about the individual web pages or products that you view, what websites or search terms referred you to the Site, and information about how you interact with the Site. Our “Use of Cookies and Similar Technologies” section contains more information and options to control or opt-out of certain data collection or uses.

You are not required to provide all Personal Data identified in this Privacy Notice in order to use the Site; however, if you do not provide the Personal Data requested, we may be unable to provide some or all of the Site to you.

USE OF COOKIES AND SIMILAR TECHNOLOGIES

The Site uses cookies and similar technologies to improve user experience, for performance and analytics, and to improve our content, products, and services. We also use cookies and similar technologies for purposes of marketing and advertising.

A “cookie” is a small text file that a web server stores in browser software. A browser sends cookies to a server when the browser makes a connection to the server (for example, when requesting a web page from the same domain that created the cookie). The purpose of cookies is to remember the browser over time and distinguish one browser instance (or user) from all others. Some cookies and other technologies may serve to track Personal Data previously entered by a web user on our site. Most browsers allow you to control cookies, including whether or not to accept them, and how to remove them. Cookies can remember login information, preferences, and similar information.

Cookies, as well as other tracking technologies, such as HTML5 local storage, and Local Shared Objects (such as “Flash” cookies), and similar mechanisms, may record information such as a unique identifier, information you enter in a form, IP address, and other categories of data.

We may also use web beacons or “pixels,” and in certain circumstances may collect IP address, screen resolution and browser software and operating system types, clickstream patterns, dates and times that our site is accessed, and other categories of data.

If you want to block the use and saving of cookies from the Site on to the computers’ hard drive, you should take the necessary steps within your web browser’s settings to block all cookies from the Site and its external serving vendors, or use the cookie control system, if available upon first visit. Please note that if you choose to erase or block your cookies, certain parts of our Site may not function correctly. For information on how to disable cookies, refer to your browser’s documentation or documentation specific to certain types of cookies (for example Flash cookies and HTML5 cookies).

Our Site may use the following technologies to implement cookies and pixels:

  • Google Analytics. In order to ensure that the content from the Site remains up to date, user-oriented and comprehensive, this Site employs Google Analytics, a web-analysis tool from Google Inc. (“Google”) that enables us to optimize our Site for you. Google Analytics uses cookies that track your preferences during your visit to our Site. This allows us to simplify navigation, for example, thereby helping us to make the site more user-friendly. The information that is generated in this process (including the IP address) is anonymized, making personal identification impossible. An evaluation for reporting purposes is carried out only after the anonymization process. The data, generated by this Cookie are usually transferred and stored on a server in the USA. As a user of our Site, you always have the option of disabling cookies in your browser settings. Most browsers allow cookies as a default setting. Should you change this setting, this may disrupt certain functions of our Site. Furthermore, you can prevent Google’s acquisition and processing of the information that is generated by the cookie and concerns your activity on the Site (including your IP address) by downloading and installing a browser plug-in. In this process, your IP-Address is in a first step reduced to Countries in the European Union or other Countries in the European Economic Community. The actual link to the tool is: http://tools.google.com/dlpage/gaoptout?hl=us. Further information on the terms of use and the privacy options of Google are available on:
    http://www.google.com/analytics/terms/us.html
  • Google AdWords. As an AdWords customer, the Site also uses Google conversion tracking by Google on some pages. This means that Google AdWords places a cookie on your computer (“conversion cookie”) if you have accessed our webpage via a Google ad. These cookies become invalid after 30 days. If you visit certain pages on our Site and the cookie has not yet expired, we and Google can recognize that someone has clicked on an ad and been directed to our page as a result thereof. Each AdWords customer receives a different cookie. Cookies can therefore not be tracked via the websites of AdWords customers. The information collected with the help of the conversion cookie allows us to prepare conversion statistics to optimize our services. AdWords customers know, for instance, the total number of customers who have clicked on their ad and been redirected to a page with a conversion tracking tag. But they do not receive any information by which users can be personally identified. If you do not want to participate in the tracking, you can prevent the placement of the necessary cookie – for instance through a browser setting that deactivates the automatic placement of cookies in general. “You can also deactivate conversion tracking cookies by setting your browser to block cookies from the domain googleadservices.com”.
  • Google Remarketing. Moreover, the Site uses Google’s Remarketing technology on some pages. With this technology, users who have already visited our web pages and online services and shown in interest in what we have to offer are shown targeted advertising on other websites of the Google Partner network. The ads are displayed through the use of cookies, by means of which the user’s behavior during his or her visit to the website is analyzed and then used for targeted product recommendations and interest-based advertising.

If you do not wish to receive any interest-based advertising, you can deactivate Google’s use of cookies for these purposes by going to https://www.google.com/settings/ads. Alternatively, users can deactivate cookies from third-party providers by going to the network advertising initiative’s deactivation page (link: https://optout.networkadvertising.org/?c=1).

Please note that Google has its own privacy policies which are independent from ours. We do not accept any responsibility or liability for these policies and procedures. Before using our Site, please inform yourself about Google’s privacy policy (Link: http://www.google.com/privacy.html).

HOW WE USE THE INFORMATION WE COLLECT

We may use Personal Data for a variety of different purposes as set out in further detail below. Subject to applicable law, the purposes for which we use and process Personal Data, and the legal basis for such processing, are set forth below.

  • For our legitimate business Interests. To operate our business and provide the Site, other than in performing our contractual obligations to you, for our legitimate business interests for the purposes of applicable law, except where such interests are overridden by the interests or fundamental rights and freedoms of the data subject which require protection of personal data. Legitimate interests may include:
    • To maintain the Site, including for technical support;
    • To communicate with you regarding the Site, including to provide you important notices regarding changes to our Terms of Use;
    • To address and respond to your requests, inquiries, and complaints;
    • To develop, provide, and improve the Site, including to better tailor the features, performance, security and support of the Site, and for statistical and analytics purposes;
    • For our direct marketing purposes;
    • In any other way we may describe when you provide the information;
    • For any other purpose with your consent;
    • For fraud, loss, and other crime prevention purposes;
    • To assist in the investigation of suspected illegal or wrongful activity, and to protect and defend our rights and property, or the rights or safety of third parties;
    • To enforce our Terms of Use, this Privacy Notice, or agreements with third parties;
    • To comply with laws, regulators, court orders, or other legal obligations, or pursuant to legal process; or
    • Subject to applicable contractual or legal restrictions, in connection with a contemplated reorganization or an actual reorganization of our business, in connection with financing, a sale or other transaction involving the disposal of all or part of our business or assets, including for the purpose of permitting the due diligence required to decide whether to proceed with a transaction.
  • To comply with legal obligations. To comply with laws, regulators, court orders, or other legal obligations, or pursuant to legal process.
  • To protect data subjects’ vital interests. To protect the vital interests of you or of another person.

In some cases where we are not already authorized to process the Personal Data under applicable law, we may ask for your consent to process your Personal Data:

  • Special Categories of Personal Data. We generally do not collect or require special categories of Personal Data (such as racial or ethnic origin, political opinions, religious or philosophical beliefs, trade union membership, health information, biometric data, or sexual orientation) in order to access our Site. In the event you voluntarily provide this information to us or we need to collect such information to provide a specific service to you, we will obtain your consent if required by law. If you choose not to provide consent, you may not be able to access all of the features and content of our Site. In certain circumstances, subject to applicable law, we may process or otherwise disclose special categories of Personal Data without consent, such as to protect the vital interests of you or of another person.
  • Cookies. We may also request consent for some cookies in accordance with our cookie policy.

HOW WE MAY DISCLOSE INFORMATION

We may disclose Personal Data as described in this Privacy Notice, including:

  • For the Purpose Disclosed. We may disclose your Personal Data to fulfill the purpose for which you provided it to us.
  • Affiliates. We may disclose some or all of your Personal Data to our subsidiaries, joint ventures, and other companies under our common control (collectively, “Affiliates”), for the purposes described in this Privacy Notice. Where we share Personal Data with our Affiliates, we will require our Affiliates to honor this Privacy Notice.
  • Service Providers. We may disclose Personal Data to business partners, distributors, service providers, marketing partners, and vendors in order to maintain, provide and improve the Site. We may also share Personal Data for other technical and processing functions, such as sending e-mails on our behalf, technical support, or otherwise operating the Site, for analytics, and for marketing purposes. Such third parties may have access to Personal Data only as needed to perform their functions for us, and they may not use Personal Data for other purposes.
  • Pursuant to Legal Process and Protection of Rights. We may also disclose Personal Data to comply with applicable laws and regulations, to respond to a subpoena, search warrant, or other lawful request for information we receive, or as otherwise pursuant to legal process. We may also use and disclose Personal Data to establish or exercise our legal rights, to enforce our Terms of Use, this Privacy Notice, or agreements with third parties, to assert and defend against legal claims, or if we believe such disclosure is necessary to investigate, prevent, or take other action regarding actual or suspected illegal or fraudulent activities or potential threats to the physical safety or well-being of any person.
  • Corporate Transactions. Subject to applicable law, we reserve the right to sell or transfer Personal Data in the event that we are acquired by or merged with another company or in connection with the potential sale or transfer of some or all of the business assets of the Site or NextPoint, including for the purpose of permitting the due diligence required to decide whether to proceed with a transaction. If the sale occurs, the purchaser will be entitled to use and disclose the Personal Data collected by us, and the purchaser will assume the rights and obligations regarding Personal Data as described in this Privacy Notice.
  • Consent. We may also disclose Personal Data with your consent.

DE-IDENTIFIED OR ANONYMOUS DATA

We may create de-identified or anonymous data from Personal Data by removing data components (such as your name, email address, or linkable tracking ID) that make the data personally identifiable to you or through obfuscation or through other means. Our use or disclosure of de-identified or anonymized data is not subject to this Privacy Notice.

DO-NOT-TRACK

Do-Not-Track is a public-private initiative that has developed a “flag” or signal that an Internet user may activate in the user’s browser software to notify websites that the user does not wish to be “tracked” by third-parties as defined by the initiative. The online community has not agreed on what actions, if any, should be taken by the websites that receive the “do not track” signal, and therefore Do-Not-Track is not yet standardized. Please note that the Site does not alter its behavior or use practices when we receive a Do Not Track signal from your browser.

INFORMATION FROM CHILDREN UNDER 13 YEARS OF AGE

We do not knowingly collect information from minors under the age of 13 years without parental consent. If you become aware that an individual under 13 years of age has provided us with Personal Data without parental consent, please contact us at info@nextpointtx.com. If we become aware that an individual under 13 years has provided us with Personal Data without parental consent, we will take steps to remove the data as permitted by law.

LINKS TO OTHER SITES

Our Site may contain links or otherwise provide access to another website, mobile application, or Internet location (collectively “Third-Party Sites”). We provide these links merely for your convenience. We have no control over, do not review, and are not responsible for Third-Party Sites, their content, or any goods or services available through the Third-Party Sites. Our Privacy Notice does not apply to Third-Party Sites. We encourage you to read the privacy policies of any Third-Party Site with which you choose to interact.

CALIFORNIA RESIDENTS

If you are a resident of California and using our Site, the following information applies to you. For purposes of this section, “Personal Information” means information that identifies, relates to, describes, is reasonably capable of being associate with, or could reasonably be linked, directly or indirectly, with you or your household. Personal Information does not include publicly available information, information that is de-identified, aggregated information, or any other information outside the scope of the California Consumer Privacy Act of 2018 (“CCPA”).

We may collect Person Information from you in a variety of ways:

Category of Personal InformationCategories of SourcesPurpose of Collecting/SharingCategories of Third Parties to Whom We Disclose Personal Information
Personal identifiers such as name, date of birth, email address, IP address, account name, online identifier, social security number, license number or other similar identifiersYou, your computer and mobile devices when you access our SiteTo allow you access to our Site and to provide you with services, such as responding to questions you may haveThird parties that help us administer and manage our Services, including third parties that help us manage our communications, complete transactions, assist with our information technology and security programs, our lawyers, accountants, auditors, or regulatory bodies or other third parties as may be required by law.
Protected classification characteristics under California or federal law such as age, gender, gender identity, gender expression, health information, educationN/AWe do not generally collect this informationN/A
Commercial information, such a Services provided, your interaction with our Site and ServicesYouTo allow you access to our Services, to provide you with Services, to respond to questions you may haveThird parties that help us administer and manage our Services, including third parties that help us manage our communications, complete transactions, assist with our information technology and security programs, our lawyers, accountants, auditors, or regulatory bodies or other third parties as may be required by law.
Biometric InformationN/AWe do not generally collect this informationN/A
Internet or other similar network activity information such as browsing history, login information, device type, accounts, IP address and other similar information concerning your interactions with our Site.Your computer and mobile devices when you visit our Site. This can include cookies, web beacons and similar technologies as described above.To analyze and improve our Services, administer our Site and Services, provide you with access to our Services, analyze and improve our information technology, monitor compliance with our Terms of Use, and enforce our Terms of Use or other legal or regulatory obligationsThird parties that help us administer and manage our Services, including third parties that help us manage our communications, complete transactions, assist with our information technology and security programs, our lawyers, accountants, auditors, or regulatory bodies or other third parties as may be required by law.
Geolocation Data such as physical location information that may be provided by the device you are usingYour computer and mobile devices when you access our Site.To analyze and improve our Services, administer our Site and Services, provide you with access to our Services, analyze and improve our information technology, monitor compliance with our Terms of Use, and enforce our Terms of Use or other legal or regulatory obligations.Third parties that help us administer and manage our Services, including third parties that help us manage our communications, complete transactions, assist with our information technology and security programs, our lawyers, accountants, auditors, or regulatory bodies or other third parties as may be required by law.
Audio, electronic, visual, thermal, olfactory or similar informationN/AWe generally do not collect this type of informationN/A
Inferences drawn from other Personal InformationYouTo analyze and improve our Services, administer our Site and Services, provide you with access to our Services, analyze and improve our information technology, monitor compliance with our Terms of Use, and enforce our Terms of Use or other legal or regulatory obligationsThird parties that help us administer and manage our Services, including third parties that help us manage our communications, complete transactions, assist with our information technology and security programs, our lawyers, accountants, auditors, or regulatory bodies or other third parties as may be required by law.

Exercising your Rights under CCPA

If you wish to exercise your rights under California law, please see the “Right to Access and Control Your Personal Information Under the European Union Data Protection Regulation (GDPR) and CCPA” section below for information on how to contact us to exercise your rights.

NextPoint does not sell your Personal Information.

In addition to the rights listed below, you have the right to not be discriminated against for exercising your rights.

Only you or a person registered with the California Secretary of State that you authorize to act on your behalf, may make a verifiable consumer request related to your personal information.

You may only make a verifiable consumer request for access or data portability twice within a 12-month period. The verifiable consumer request must:

  • Provide sufficient information that allows us to reasonably verify you are the person about whom we collected personal information or an authorized representative.
  • Describe your request with sufficient detail that allows us to properly understand, evaluate, and respond to it.

California Shine the Light Law:

California Civil Code Section 1798.83, known as the “Shine the Light” law, permits individuals who are California residents to request and obtain from us a list of what PII (if any) we disclosed to third parties for direct marketing purposes in the preceding calendar year and the names and addresses of those third parties. We will never disclose your PII to third parties for direct marketing purposes without your authorization. However, if you would like to make a request for information under the Shine The Light law, please contact us at the “Contact Us” section below.

Requests may be made only once a year and are free of charge.

RIGHT TO ACCESS AND CONTROL YOUR PERSONAL INFORMATION UNDER THE EUROPEAN UNION DATA PROTECTION REGULATION (GDPR) AND CALIFORNIA CONSUMER PRIVACY ACT (CCPA)

Individuals in California, the EU and certain other jurisdictions who are accessing this site and whose data we may be collecting and processing may have certain rights under applicable data protection law, including the right to request confirmation from us as to whether or not we are processing your Personal Data. Where we are processing your Personal Data, subject to applicable law, you also have the right to:

  • Request access to, modification or rectification, or deletion. You may have the right to request access to, modification of, correction of, or deletion of your Personal Data we maintain.
  • Request restriction of processing. You may have the right to request that we restrict processing of your Personal Data in certain circumstances, such as where you believe that the Personal Data we hold about you is inaccurate or our processing is unlawful.
  • Object to processing. In certain circumstances, you may have the right to request that we stop processing your Personal Data, such as a request to stop sending you direct marketing communications. To opt-out of direct marketing communications, please see the instructions in the “Withdrawing Your Consent” section of this Privacy Notice.
  • Data portability. In certain circumstances, you may have the right to receive the Personal Data concerning you that you provided to us or to request that we transmit your Personal Data to another data controller.
  • Lodge a Complaint. You have the right to lodge a complaint with a supervisory authority.

 

To exercise your rights, you may contact us as at info@nextpointtx.com. As permitted by law, certain data elements may not be subject to access, modification, portability, restriction, and/or deletion. Furthermore, where permissible, we may charge for this service. We will respond to reasonable requests as soon as practicable and as required by law. To protect your privacy and security, we may take steps to verify your identity in order to respond to your request. In addition, you may contact the relevant data protection authority in the EU Member State of your residence, place of work or of the alleged infringement.

WITHDRAWING YOUR CONSENT

In most cases, we need to process certain components of your Personal Data in order to fulfill our contractual obligations to you and for our legitimate interests. Please note that, subject to applicable law, we may continue to process your Personal Data even where you object if there are compelling legitimate grounds for processing that override your interests and rights, or where processing is necessary to establish, exercise, or defend legal claims.

Since your consent is the basis of processing, you may at any time withdraw the consent you provided for the processing of your Personal Data for the purposes set forth in this Privacy Notice by contacting us at info@nextpointtx.com, provided that we are not required by applicable law or professional standards to retain such information.

If you would like to stop receiving newsletters or other marketing or promotional messages, notifications, or updates, you may do so by following the unsubscribe instructions that appear in these e-mail communications. Alternatively, you may contact us at info@nextpointtx.com to opt-out of direct marketing. Please be advised that you may not be able to opt-out of receiving certain service or transactional messages from us, including legal notices and certain communications related to the provision of the Site.

Please note that if you do not provide consent, if you withdraw your consent or object to processing, or if you choose not to provide certain Personal Data, we may be unable to provide you some or all of the Site.

TRANSFER OF DATA

Please note that if you are visiting the Site from outside of the United States, your information may be transferred to, stored, and/or processed in the US. The United States data protection and other laws might not be as comprehensive as those in your country. If you are located outside of the United States, the transfer of Personal Data is necessary to provide you with the requested information and Site and/or to perform any requested transaction. By using any portion of the Site, you acknowledge and consent to the transfer of your information to our facilities in the United States.

DATA RETENTION

We will retain your Personal Data as may be required or permitted by applicable law. We will also retain your Personal Data as necessary to comply with our legal obligations, resolve disputes, and enforce our agreements.

SECURITY

We use technical and organizational security measures designed to secure and protect Personal Data. Please note, however, we cannot fully eliminate security risks associated with the storage and transmission of Personal Data.

UPDATES TO THIS PRIVACY NOTICE

We may update this Privacy Notice from time to time. The most recent version of the Privacy Notice is reflected by the version date located at the top of this Privacy Notice. We encourage you to review this Privacy Notice often to stay informed of how we may process your information.

CONTACT US

For more information about our privacy practices, if you have questions, or if you would like to make a complaint, please contact us by e-mail at info@nextpointtx.com or by mail at the following address:

NextPoint Therapeutics, Inc.
450 Kendall Street
Cambridge, MA 02142